SCM
DCOY

Silverarc Capital Management’s Decoy Therapeutics DCOY Stock Holding History

Silverarc Capital Management’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13
Closed -$500K – 104
2021
Q2 		$500K Sell
13
-42
-76% -$1.87M 0.22% 82
2021
Q1 		$2.95M Buy
+55
New +$3.15M 1.61% 24

Other funds holding DCOY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return

Silverarc Capital Management's DCOY Position: Q3 2021 in Review

Silverarc Capital Management sold out of Decoy Therapeutics (DCOY) in Q3 2021, closing a stake of 13 shares — an estimated $500K sold.

Silverarc Capital Management first reported a position in DCOY in Q1 2021 and held it in 2 quarters. The position peaked at $2.95M in Q1 2021. 20 funds tracked by Wall St. Rank hold DCOY as of Q3 2021.

  • Silverarc Capital Management reported no remaining Decoy Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 13 Decoy Therapeutics shares in Q3 2021, an estimated $500K.
  • Silverarc Capital Management first reported a position in Decoy Therapeutics in Q1 2021 and held it in 2 quarters.
  • Silverarc Capital Management's Decoy Therapeutics position peaked at $2.95M in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q3 2021.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.